



Stabilis



Meropenem Vaborbactam



Noms commerciaux

Vaborem

Etats Unis d'Amérique, France



Compatibilités

	Meropenem Vaborbactam : 8 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
	Meropenem Vaborbactam : 8/8 mg/ml Eravacycline : 0,6 mg/ml		4434
	Meropenem Vaborbactam : 8/8 mg/ml Plazomicin sulfate : 24 mg/ml		4145
	Meropenem Vaborbactam : 8/8 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801

















Bibliographie

	Type	Source
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056

4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Compatibilités
 Molécule	 Solvant
 Bibliographie	 Compatible
 NaCl 0,9% ou glucose 5%	 Turbidité immédiate
 Incompatible	 Chlorure de sodium 0,9%
 Bibliographie	 Dictionnaire